A Phase 2 interventional study of Semaglutide (Wegovy®) and Placebo (saline) in Infertility in Overweight Men, sponsored by Copenhagen University Hospital at Herlev. Not yet recruiting at 1 site in Denmark. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Copenhagen University Hospital at Herlev · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Overweight and obesity are associated with functional hypogonadism and impaired semen quality. Although lifestyle interventions may improve reproductive function, long-term adherence is often challenging. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), increasingly used to treat obesity, have shown promising effects on weight loss, testosterone levels and potentially semen quality through both direct and indirect mechanisms. However, clinical evidence regarding their effects on male fertility remains limited.
The SemenGlutide trial is a randomised, double-blinded, placebo-controlled, single-centre clinical trial investigating whether once-weekly subcutaneous semaglutide improves semen quality in overweight infertile men, compared with placebo.
It is estimated that around 10-20 percentage of couples worldwide experience infertility. In up to 30-50 percent of these cases, the male is a significant contributing factor. Very few new treatment modalities are being developed to improve semen quality or sperm function despite the significant male contribution to the infertility problem and the observed global decline in semen quality. While assisted reproductive technology (ART) has improved tremendously, these techniques only focus on treating the female even when the male is the only cause of infertility. While infertility is defined at the couple level, male fertility potential is typically evaluated by routine semen analyses where sperm concentration, sperm motility and morphology are assessed. Men with overweight often struggle with functional hypogonadism and possible direct testicular effects resulting in impaired semen quality. Functional hypogonadism is a potentially reversible condition characterised by mild to moderately low testosterone levels with low-to-normal luteinizing hormone (LH) levels thought to originate from age and/or lifestyle-related comorbidities, including obesity and metabolic syndrome. To maintain normal spermatogenesis, a functioning hypothalamic-pituitary-gonadal (HPG) axis is required. It is known that obesity can affect and impair the HPG axis, however, the mechanism of the proposed potential concomitant impaired semen quality has been discussed regarding inflammation or the direct effect of an impaired HPG-axis, playing the main role. Overweight and obese men have functional or hypogonadotropic hypogonadism phenotype that can lead to reduced semen quality. Lifestyle interventions can be effective, but compliance with these interventions is difficult, and many men fail in the long term. Recent advances in knowledge of the effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) suggest that this class of drugs can improve hypogonadism and maybe also semen quality in overweight and obese men by both direct and indirect effects. GLP-1RAs are being used more frequently, and new roles in non-classical targets are emerging. A recent systematic review and meta-analysis investigating the effect of GLP-1RAs on testosterone in males suffering from overweight/obesity showed that treatment with GLP-1RAs resulted in weight loss, improved testicular function and a possible favourable effect on testosterone and gonadotropins. Considering this, weight loss medication is possibly a favourable tool to use in overweight patients with male infertility irrespective of the presence of obesity. GLP-1RA, Semaglutide, is approved for the management of overweight/obesity in doses up to 2.4 mg and induces substantial weight loss. GLP-1RA administration increases hypothalamic kisspeptin expression and stimulates gonadotropin-releasing hormone (GnRH) secretion in rodent studies. In addition, Semaglutide may have a direct testicular effect that appears to be beneficial, as shown by data from the Division of Translational Endocrinology, Herlev but also a study by Signe Torekovs group showing improved semen quality in men with normal fertility following weight loss and liraglutide treatment.
SemenGlutide is a randomised double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of subcutaneous (s.c.) Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men. The study aims to investigate whether semaglutide can improve semen quality in infertile men with a body mass index (BMI) of at least 27 kg/m\^2. The hypothesis is that semaglutide treatment will result in a greater increase in sperm production compared with placebo.
Following confirmation of eligibility and obtained informed consent, participants will be randomised at baseline in a 1.5:1 ratio to receive either semaglutide or placebo. Participants will receive the study medication for self-administration at home throughout the trial, with regular dispensing by trained study personnel. The dose will be gradually titrated to the target dose of 2.4 mg semaglutide or corresponding placebo. A total of 150 men will be enrolled, with at least 120 expected to complete the trial. This sample size will provide 80 percent power to detect a 65 percent greater increase in sperm concentration in the semaglutide group compared with placebo at day 200, using a significance level of 5 percent.
Safety is evaluated throughout the study using repeated clinical assessments, laboratory monitoring, and systematic recording of adverse events. All side effects will be closely monitored and reported. The study is approved by the regional ethical committee, conducted in compliance with The Declaration of Helsinki and monitored by the Good Clinical Practice unit of Copenhagen University Hospitals.
1,820 studies on the registry are indexed under Weight Loss; 298 are open to participants now.
This study's planned enrollment of 150 is above the median of 80 across 1,566 interventional studies indexed under Weight Loss.
Browse Weight Loss studies →Copenhagen University Hospital at Herlev is the lead sponsor of 78 studies on the registry; 10 are open to participants now.
Compared within Weight Loss, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Semaglutide 2.4 mg administered subcutaneously once weekly
Drug: Semaglutide (Wegovy®)
Saline administered subcutaneously once weekly
Drug: Placebo (saline)
Titration algorithms are used in order to ensure participants receive optimal treatment with minimal side-effects. Patients will recieve full dosage of 2.4mg a week from week 16 to week 43.
Titration algorithms similar to those used in the intervention group will be applied to maintain blinding. Participants will receive the full target dose once weekly from week 16 to week 43.
Difference in sperm concentration or total sperm count on day 200
Difference in sperm production evaluated by sperm concentration (millions/mL) or total sperm count (millions) measured by semen analysis.
Time frame: From baseline to day 200
Difference in sperm concentration from baseline to day 300
Difference in sperm concentration (millions/mL) evaluated by semen analysis
Time frame: From baseline to day 300
Differences and changes in DNA fragmentation index (%) from baseline to day 300
Time frame: From baseline to day 200 and 300
Changes in sperm parameters from baseline to day 300
Measured by number (millions)
Time frame: From baseline to day 100, 200 and 300
Differences in sperm production from baseline to day 300
Sperm concentration (million/mL) evaluated by the automated CASA SCA (Microptic) system
Time frame: From baseline to day 200 and 300
Differences in body mass index (BMI) from baseline to day 300
Weight (kg) and height (cm) is measured at each visit during the trial, and will be combined to report BMI
Time frame: From baseline to day 100, 200 and 300
Differences in total body fat percentage (%) from baseline to day 300
Evaluated by dual-energy x-ray absorptiometry (DXA) scan
Time frame: From baseline to day 300
Differences in bone mineral density (BMD) g/cm^2 from baseline to day 300
Evaluated by DXA scan
Time frame: From baseline to day 300
Changes in subjective symptoms of androgen deficiency from baseline to day 300
Assessed using Androgen Deficiency in the Aging Male questionnaire (ADAM). The summation of the responses yields a total ADAM score between 10 and 50, with 10 being most symptomatic and 50 being least symptomatic.
Time frame: From baseline to day 300
Changes in male sexual function from baseline to day 300
Assessed using The International Index of Erectile Function questionnaire (IIEF-5). The possible scores for the IIEF-5 range from 5 to 25, and erectile dysfunction (ED) is classified into five categories based on the scores: severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no ED (22-25).
Time frame: From baseline to day 300
Changes in total testosterone (nmol/L) and free testosterone (nmol/L) from baseline to day 300
Measured by blood sample
Time frame: From baseline to day 100, day 200 and day 300
Differences in luteinizing hormone (IU/L) and follicel stimulating hormone (IU/L) from baseline to day 300
Measured by bloodsample.
Time frame: From baseline to day 100, day 200 and day 300
Differences in HbA1c from baseline to day 300
Measured by bloodsample.
Time frame: From baseline to day 100, day 200 and day 300
Differences in lipid profile from baseline to day 300
Differences in total cholesterol (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L) and triglycerides (mmol/L). Measured by bloodsample.
Time frame: From baseline to day 100, day 200 and day 300
Changes in sperm parameters from baseline to day 300
Measured by motility (%) by semen analysis
Time frame: From baseline to day 100, 200 and 300
Changes in sperm parameters from baseline to day 300
Measured by morphology (%) by semen analysis
Time frame: From baseline to day 100, 200 and 300
Differences in sperm production from baseline to day 300
Total sperm count (million) evaluated by the automated CASA SCA (Microptic) system
Time frame: From baseline to day 200 and 300
Differences in sperm production from baseline to day 300
Total motile sperm (%) evaluated by the automated CASA SCA (Microptic) system
Time frame: From baseline to day 200 and 300
Differences in total muscle mass (kg) from baseline to day 300
Evaluated by DXA scan
Time frame: From baseline to day 300
Differences in trabecular bone score (TBS) from baseline to day 300
Evaluated by DXA scan. A normal TBS is defined as \>1.350 (no units) where TBS bewteen 1.200 and 1.350 is defined as partially degraded bone.
Time frame: From baseline to day 300
Differences in sex hormone binding globulin (SHBG) (nmol/L) from baseline to day 300
Measured by bloodsample.
Time frame: From baseline to day 100, day 200 and day 300
Differences in Anti-Müllerian Hormone (AMH) (pmol/L) from baseline to day 300
Measured by bloodsample.
Time frame: From baseline to day 100, day 200 and day 300
Differences in inhibin B (ng/L) from baseline to day 300
Measured by bloodsample.
Time frame: From baseline to day 100, day 200 and day 300
Differences in HOMA-IR from baseline to day 300
HOMA-IR will be calculated as follows: (plasma insulin (µIU/mL) × plasma glucose (mg/dL)) / 405 = HOMA-IR. Values \<1.0 indicate optimal insulin sensitivity, 1.0-1.9 indicate mild insulin resistance, 2.0-2.9 indicate moderate insulin resistance, and \>3.0 indicate significant insulin resistance.
Time frame: From baseline to day 100, day 200 and day 300
Changes in circulating markers of bone resorption and formation from baseline to day 300
Changes in procollagen type I N-terminal propeptide (PINP), Receptor Activator of Nuclear Factor κB Ligand (RANKL), Osteoprotegerin (OPG) and C-terminal telopeptide of type I collagen (CTX) measured by bloodsample
Time frame: From baseline to day 100, day 200 and day 300
Changes in calcium homeostasis and spoturine from baseline to day 300
Measured by serum (albumin, calcium, phosphate) and urine (calcium, iron, ferritin, zinc, magnesium, phosphate, sodium and creatinine)
Time frame: From baseline to day 100, day 200 and day 300
Change in mineral homeostasis from baseline to day 300
Changes in serum iron, ferritin, hepcidin, transferrin, magnesium, zinc, measured by bloodsample
Time frame: From baseline to day 100, day 200 and day 300
Changes in calciotropic hormones from baseline to day 300
Changes in serum 25OHD, parathyroid hormone (PTH), Klotho and fibroblast growth factor 23 (FGF23), measured by bloodsample
Time frame: From baseline to day 100, day 200 and day 300
Changes in serum vitamin D metabolites from baseline to day 300
Changes in serum cholecalciferol, 25OHD, 24,25OHD 1,25OHD and cholecalciferol/25OHD ratio, 25OHD/24,25OHD ratio, measured by bloodsample
Time frame: From baseline to day 100, day 200 and day 300
Changes in androstenedione, progesterone, cortisol, cortisone and dehydroepiandrosterone sulfate (DHEAS) from baseline to day 300
Measured by bloodsample
Time frame: From baseline to day 100, day 200 and day 300
Changes in 11-oxy-androgens and androgens from the alternative pathway from baseline to day 300
Measured by bloodsample
Time frame: From baseline to day 100, day 200 and day 300
Changes in thyroid stimulating hormone (TSH), T3, T4, CBG, TBG, INSL-3, Prolactin from baseline to day 300
Measured by bloodsample
Time frame: From baseline to day 100, day 200 and day 300
Changes in seminal fluid of minerals and hormones from baseline to day 300
Seminal fluid
Time frame: From baseline to day 100, day 200 and day 300
Plan to share: No
Start is estimated for Jan 2027; primary completion for Jun 2029, 29 months later.
Of 44 phase 2 interventional studies under Weight Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 29 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
Copenhagen University Hospital at Herlev